

		Unadjusted					Adjusted for BC1 ¹					Adjusted for BC1 and BC2 ²					
Patient group		HR	n	Events	95% CI	<i>p</i> _{HR}	<i>p</i> _i	HR	n	Events	95% CI	<i>p</i> _{HR}	HR	n	Events	95% CI	<i>p</i> _{HR}
GPR30_{TOI}	ER+ BC2	1.2	492	177	0.86-1.8	0.2	0.7	0.95	349	126	0.59-1.5	0.8	1.1	282	105	0.66-1.9	0.7
	ER- BC2	1.1	99	60	0.63-1.9	0.8		1.4	75	45	0.74-2.7	0.3	3.0	67	40	1.4-6.6	0.006
	ER+, tamoxifen for BC2	1.4	70	35	0.60-3.5	0.4	0.4	0.55	123	45	0.18-1.6	0.3	1.1	45	24	0.30-4.0	0.26
	ER+, no tamoxifen for BC2	1.3	48	26	0.39-4.4	0.7		1.1	224	79	0.94-1.9	0.8	7.9	35	21	1.1-60	0.04
GPR30_{PM}	ER+ BC2	1.8	492	177	0.88-3.6	0.1	0.1	1.8	349	126	0.80-3.9	0.2	1.9	282	105	0.76-4.5	0.2
	ER- BC2	0.87	99	60	0.45-1.7	0.7		1.1	75	45	0.47-2.4	0.8	1.3	67	40	0.55-3.2	0.5
	ER+, tamoxifen for BC2	0.51	180	63	0.07-3.7	0.5	0.3	0.27	123	45	0.030-2.5	0.3	0.57	104	40	0.06-5.3	0.6
	ER+, no tamoxifen for BC2	2.8	310	112	1.3-6.0	0.01		2.2	224	79	0.90-5.6	0.08	3.8	176	63	1.4-11	0.01

¹ Adjusted for GPR30 intensity, age and calendar interval of diagnosis, tumor size, node status, HER2 status and Ki67 staining of BC1. ² Adjusted for GPR30 intensity, size, node status, HER2 status and ki67 staining of BC1 and BC2, as well as age and calendar interval at BC2 diagnosis and interval between BC1 and BC2.

*p*_i: *p*_{interaction}. Level of evidence that GPR30 has different effect in the compared groups.